Vizient has ranked Rush University Medical Center #1 for quality among the nation’s most prestigious academic medical centers. Learn more.

Excellence is just the beginning.

Translate

French German Italian Portuguese Russian

Treatment Study for Patients with Ovarian Cancer

Clinical Trial Title: 
ATHENA: A multicenter, randomized, double-blind, placebo-controlled phase 3 study in ovarian cancer patients evaluating rucaparib and nivolumab as maintenance treatment following response to front-line platinum-based chemotherapy.
Clinical Trial Protocol ID: 
18031202
Clinical Trial Investigator Name: 
Lydia Usha, MD
Clinical Trial Protocol Description: 

This is a phase 3, randomized, multinational, double-blind, dual placebo-controlled, 4-arm study evaluating rucaparib and nivolumab as maintenance treatment following response to front-line treatment in newly diagnosed ovarian cancer patients. Response to treatment will be analyzed based on homologous recombination (HR) status of tumor samples.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Have newly diagnosed advanced (FIGO stage III-IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer.
  • Have completed cytoreductive surgery, including at least a bilateral salpingo-oophorectomy and partial omentectomy, either prior to chemotherapy (primary surgery) or following neoadjuvant chemotherapy (interval debulking).
  • Have completed first-line platinum-based chemotherapy and surgery with a response, in the opinion of the Investigator.
  • Have sufficient tumor tissue for planned analysis.

You will be excluded from the study if any of the following criteria apply to you:

  • Have pure sarcomas or borderline tumors or mucinous tumors.
  • Have active second malignancy.
  • Have known central nervous system brain metastases.
  • Have any prior treatment for ovarian cancer, other than the first-line platinum regimen.

This is a partial list of inclusion and exclusion criteria.

Clinical Trial Area: 
Gynecologic Cancers
Contact Phone: 
(312) 942-2417
Contact Name: 
Lois Winkelman